Three trials worth keeping an eye on, all updated recently.
## Indiana University: Psilocybin for TRD with Co-Occurring Substance Use
A new [Phase 1/2 trial at Indiana University (NCT07499583)](https://clinicaltrials.gov/study/NCT07499583) will test psilocybin-assisted psychotherapy in a population that most studies explicitly exclude: people with treatment-resistant depression and active substance use disorder. The trial targets veterans and first responders. Dose comparison: 5mg, 10mg, and 25mg across 50 participants. Estimated start August 2026.
The co-morbidity angle matters. In standard trials, active SUD is typically an exclusion criterion for safety reasons and to keep study populations clean. Studying both conditions together in a high-risk population is a meaningful design choice — results will be relevant to real-world patients who don't fit cleaner trial profiles.
## Johns Hopkins Psilocybin for OCD — Nearing Completion
The [Johns Hopkins psilocybin-for-OCD study (NCT05546658)](https://clinicaltrials.gov/study/NCT05546658) has stopped recruiting and has a primary completion date of September 2026. It's an early-phase feasibility study — small, not powered for definitive efficacy conclusions — but Hopkins OCD research has historically been influential in shaping what follows.
## UC Irvine Ibogaine Neuroimaging Study
UC Irvine has registered a [study (NCT07226570)](https://clinicaltrials.gov/study/NCT07226570) examining what ibogaine does to the brain in people with opioid use disorder. Notably, UCI isn't administering the drug — participants will receive ibogaine treatment at a licensed clinic outside the US, and UCI researchers will conduct neuroimaging before and after. Twenty participants.
Ibogaine is illegal in the US but used clinically in Mexico and other countries, and generating genuine interest from the VA and DoD for opioid use disorder and TBI applications. Getting cleaner neuroimaging data on its mechanisms is a reasonable precursor to any domestic regulatory pathway.